Generation of iPSC lines from archived non-cryoprotected biobanked dura mater
Open accessThe DOI matches its Crossref record; 13 of the 14 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Induced pluripotent stem cells (iPSCs) derived from patients with neurodegenerative disease generally lack neuropathological confirmation, the gold standard for disease classification and grading of severity. The use of tissue with a definitive neuropathological diagnosis would be an ideal source for iPSCs. The challenge to this approach is that the majority of biobanked brain tissue was not meant for growing live cells, and thus was not frozen in the presence of cryoprotectants such as DMSO. RESULTS: We report the generation of iPSCs from frozen non-cryoprotected dural tissue stored at -80°C for up to 11 years. This autopsy cohort included subjects with Alzheimer's disease and four other neurodegenerative diseases. CONCLUSIONS: Disease-specific iPSCs can be generated from readily available, archival biobanked tissue. This allows for rapid expansion of generating iPSCs with confirmed pathology as well as allowing access to rare patient variants that have been banked.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Furthermore, iPSC-derived cell types from different lineages can be combined into defined three-dimensional cultures, termed assembloids9,94–98.”
From CRISPR-based functional genomics for neurological disease (2020) · cites this paper as [97]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 1×
“typical of AD (sporadic late-onset), including aggregated frequent amyloid plaques (CERAD plaque score C [9]) and severe accumulation and progression of phospho-tau inclusions (Braak neurofibrillary tangle stage VI, Figure 2A [10]).”
Mirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961 · cited 1×
“typical of AD (sporadic late-onset), including aggregated frequent amyloid plaques (CERAD plaque score C [9]) and severe accumulation and progression of phospho-tau inclusions (Braak neurofibrillary tangle stage VI, Figure 2A [10]).”
Kalluri, R., & Zeisberg, M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1877 · Cited by 4,538 · cited 1×
“Comparing nine genes commonly used as functional fibroblast markers [7] reveals that most are present at similar levels in scalp and dural cells, with the exception of FSP1 (Additional file 1).”
Ban, H., Nishishita, N., Fusaki, N., Tabata, T., Saeki, K., Shikamura, M., Takada, N., Inoue, M., Hasegawa, M., Kawamata, S., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1103509108 · Cited by 605 · cited 1×
“Next, we attempted to reprogram skin and dural lines into a pluripotent state using a Sendai virus integrationfree method [8].”
Biobanking: the foundation of personalized medicine
Hewitt, R. E. (2011) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32834161b8 · Cited by 288 · cited 1×
“medicine and associated genetic studies, which require large biorepositories, has accelerated the rate of establishment of new facilities [11,12].”
The neuropathology, pathophysiology and genetics of multiple system atrophy
Ahmed, Z., Asi, Y. T., Sailer, A., Lees, A. J., Houlden, H., Revesz, T., & Holton, J. L. (2012) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2011.01234.x · Cited by 274 · cited 1×
“This patient had multiple system atrophy (MSA), a fatal disease characterized by glial cytoplasmic inclusions composed of α-synuclein that affects the striatum and other brain regions [6] (Figure 1A-D).”
Characterizing biobank organizations in the U.S.: results from a national survey
Henderson, G. E., Cadigan, R. J., Edwards, T. P., Conlon, I., Nelson, A. G., Evans, J. P., Davis, A. M., Zimmer, C., & Weiner, B. J. (2013) · Genome Medicine · doi:10.1186/gm407 · Cited by 198
Twenty-first century brain banking. Processing brains for research: the Columbia University methods
Vonsattel, J. P. G., del Amaya, M. P., & Keller, C. E. (2008) · Acta Neuropathologica · doi:10.1007/s00401-007-0311-9 · Cited by 169
Self-citationVonsattel, J. P., Amaya, M. D. P., Cortes, E. P., Mancevska, K., & Keller, C. E. (2008) · Cell and Tissue Banking · doi:10.1007/s10561-008-9079-y · Cited by 77
Self-citationKahler, D. J., Ahmad, F. S., Ritz, A., Hua, H., Moroziewicz, D. N., Sproul, A. A., Dusenberry, C. R., Shang, L., Paull, D., Zimmer, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059867 · Cited by 56 · cited 3×
“Results Generation of iPSCs from skin biopsies is routinely preformed by our and many other laboratories [5], but whether iPSCs with similar properties can be generated from meninges was unclear.”
Self-citation
Research works printed but not linked: 1
- Henderson GE, Cadigan RJ, Edwards TP: Genome medicine. 2013, 5(1):3.
Cited by
CRISPR-based functional genomics for neurological disease
Kampmann, M. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0373-z · Cited by 163
Accelerating stem cell trials for Alzheimer's disease
Hunsberger, J. G., Rao, M., Kurtzberg, J., Bulte, J. W. M., Atala, A., LaFerla, F. M., Greely, H. T., Sawa, A., Gandy, S., Schneider, L. S., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00332-4 · Cited by 97
Pistollato, F., Ohayon, E. L., Lam, A., Langley, G. R., Novak, T. J., Pamies, D., Perry, G., Trushina, E., Williams, R. S. B., Roher, A. E., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9175 · Cited by 77
“iPSCs have been successfully obtained by reprogramming frozen noncryoprotected dural tissue samples (stored at −80°C for up to 11 years), which allowed for generating iPSCs with confirmed pathology even from AD patients with rare genetic variants [72].”
BackgroundThe application of in vitro ‐derived human neurons in neurodegenerative disease modeling
D’Souza, G. X., Rose, S. E., Knupp, A., Nicholson, D. A., Keene, C. D., & Young, J. E. (2020) · Journal of Neuroscience Research · doi:10.1002/jnr.24615 · Cited by 39
“…al., 2012), CD34+ cells from peripheral blood (Loh et al., 2009) and renal proximal epithelial cells from urine (Zhou et al., 2011). hiPSCs lines have also been established from postmortem tissue including dura mater (Bliss et al., 2012; Sproul et al., 2014) and leptomeninges (Rose et al., 2018).”
BackgroundCurrent trends in biobanking for rare diseases: a review
Graham, C., Dawkins, H. J. S., Baynam, G. S., Lockmuller, H., Bushby, K. M. D., Monaco, L., Zatloukal, K., Rubinstein, Y., Mora, M., Knoppers, B. M., et al. (2014) · Journal of Biorepository Science for Applied Medicine · doi:10.2147/bsam.s46707 · Cited by 31
Metadata
- Authors
- Sproul, A. A., Vensand, L. B., Dusenberry, C. R., Jacob, S., Vonsattel, J. P. G., Paull, D. J., Shelanski, M. L., Crary, J. F., & Noggle, S. A.
- Affiliations
- New York Stem Cell Foundation (US)
- Columbia University (US)
- Corresponding author
- Crary, John F
- Noggle, Scott A
- Venue
- Acta Neuropathologica Communications
- Published
- 2014-01-07
- Volume
- 2
- Issue
- 1
- Pages
- 4-4
- ISSN
- 2051-5960 (ISSN-L)
- PMC
- PMC3895779
- OpenAlex
- W2141823770
- Cited by
- 27
- References
- 14
- Citations by year
- 2025: 1 · 2022: 1 · 2021: 2 · 2020: 7 · 2019: 3 · 2018: 3 · 2017: 2 · 2016: 2 · 2015: 4 · 2014: 2
- FWCI
- 1.37
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Acta Neuropathologica Communications (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- National University of Singapore (submittedVersion, cc-by)
- Columbia Academic Commons (Columbia University)
- Funders
- Alzheimer's Association (NIRG-11-204450)
- New York Stem Cell Foundation
- Cure Alzheimer's Fund
- National Institutes of Health
- National Institute on Aging (RF1AG042965, RO1AG037212, R01AG037212, P50AG008702, P50AG08702)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Life Sciences › Neuroscience › Developmental Neuroscience › Neurogenesis and neuroplasticity mechanisms
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- induced pluripotent stem cells, dura mater, Alzheimer's disease, neurodegenerative diseases, neuropathological diagnosis, tissue banking
- MeSH terms
- Nanog Homeobox Protein, Alzheimer Disease, Animals, Antigens, Surface, Cell Differentiation, Cell Line, Transformed, Dura Mater, Fibroblasts, Humans, Postmortem Changes, Proteoglycans, Skin, Homeodomain Proteins, Neurodegenerative Diseases, Databases as Topic, Cell Proliferation, Octamer Transcription Factor-3, Mice, Stage-Specific Embryonic Antigens, Induced Pluripotent Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Generation of iPSC lines from archived non-cryoprotected biobanked dura mater. https://app.cochat.ai/papers/10.1186/2051-5960-2-4
- The paper
- Sproul, A. A., Vensand, L. B., Dusenberry, C. R., Jacob, S., Vonsattel, J. P. G., Paull, D. J., Shelanski, M. L., Crary, J. F., & Noggle, S. A. (2014). Generation of iPSC lines from archived non-cryoprotected biobanked dura mater. Acta Neuropathologica Communications. https://doi.org/10.1186/2051-5960-2-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.